Cost-effectiveness of lung transplantation in The Netherlands: a scenario analysis by Al, M.J. (Maiwenn) et al.
 1998;113;124-130 Chest
EM TenVergert 
MJ Al, MA Koopmanschap, PJ van Enckevort, A Geertsma, W van der Bij, WJ de Boer and
 Cost-effectiveness of lung transplantation in The Netherlands: a scenario analysis
This information is current as of December 12, 2006 
 http://www.chestjournal.org
the World Wide Web at: 
The online version of this article, along with updated information and services, is located on
without the prior written permission of the copyright holder. ISSN: 0012-3692. 
Northbrook IL 60062. All rights reserved. No part of this article or PDF may be reproduced or distributed
monthly since 1935. Copyright 2005 by the American College of Chest Physicians, 3300 Dundee Road, 
CHEST is the official journal of the American College of Chest Physicians. It has been published
 at Swets Subscription Service on December 12, 2006 www.chestjournal.orgDownloaded from 
Cost-effectiveness of Lung
Transplantation in the Netherlands*
A Scenario Analysis
Maiwenn J. Al, MSc; Marc A. Koopmanschap, PhD; Petra J. van Enckevort, MSc;
Albert Geertsma, MD, PhD; Wim van der Bij, MD, PhD; Wim J. de Boer, MD;
and Els M. TenVergert, PhD
Study objectives: To calculate cost-effectiveness of scenarios concerning lung transplantation in
the Netherlands.
Design: Microsimulation model predicting survival, quality of life, and costs with and without
transplantation program, based on data of the Dutch lung transplantation program of 1990 to
1995.
Setting: Netherlands, University Hospital Groningen.
Patients: Included were 425 patients referred for lung transplantation, of whom 57 underwent
transplantation.
Intervention: Lung transplantation.
Results: For the baseline scenario, the costs per life-year gained are G 194,000 (G5Netherlands
guilders) and the costs per quality-adjusted life-year (QALY) gained are G 167,000. Restricting
patient inflow (“policy scenario”) lowers the costs per life-year gained: G 172,000 (costs per QALY
gained: G 144,000). The supply of more donor lungs could reduce the costs per life-year gained
to G 159,000 (G 135,000 per QALY gained; G15US$0.6, based on exchange rate at the time of the
study).
Conclusions: Lung transplantation is an expensive but effective intervention: survival and quality
of life improve substantially after transplantation. The costs per life-year gained are relatively
high, compared with other interventions and other types of transplantation. Restricting the
patient inflow and/or raising donor supply improves cost-effectiveness to some degree. Limiting
the extent of inpatient screening or lower future costs of immunosuppressives may slightly
improve the cost-effectiveness of the program. (CHEST 1998; 113:124-30)
Key words: cost-effectiveness; cost utility; lung transplantation; microsimulation; scenario-analysis
Abbreviations: QALY5quality-adjusted life-year
L ung transplantation is a fast-growing and expen-sive medical intervention. Worldwide, about
6,000 lung transplants have been performed in more
than 100 centers.1 However, reliable information on
cost-effectiveness of lung transplantation programs is
lacking. To our knowledge, only one retrospective
pilot study on this topic was published thus far.2 Its
small sample size and limited cost-analysis prohib-
ited firm conclusions. In this article, we will estimate
the cost-effectiveness of various scenarios of future
lung transplantation, based on detailed data from a
large technology assessment of the Dutch lung trans-
plantation program, as performed during 1990 to
1995.3 This study was initiated by the Dutch Na-
tional Health Insurance Board, to support public
reimbursement decisions.
The scenario analysis describes future transplan-
tation programs, operational for 15 years. This sim-
ulation period is necessary to reach a stable number
of patients on the waiting list, which has not yet been
established during the observation period. Societal
costs, survival, and quality of life are followed up to
40 years, comparing the situation with and without a
lung transplantation program.
Several scenarios will be presented: a baseline
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scenario, a prolongation of the current program; a
policy-scenario, restricting the inflow of patients on
the waiting list; and a donor scenario, assuming a
larger supply of donor lungs.
Materials and Methods
From November 1990 until April 1995, data were gathered on
all patients who entered the Dutch lung transplantation program.
Patients are eligible for the program if they have irreversible,
progressively disabling, end-stage pulmonary or cardiopulmonary
disease with a predicted life expectancy of ,12 to 18 months.4
The first phase of the program is the application phase in which
potential candidates are identified on the basis of written infor-
mation of the referring physician. The other phases of the
program are outpatient screening, inpatient screening, pretrans-
plantation, waiting list, transplantation (perioperative and inten-
sive care), inpatient follow-up, and outpatient follow-up. A total
of 425 patients was referred to the program. Of these patients,
303 entered the outpatient screening phase and 179 were
accepted for the inpatient screening. One hundred twenty pa-
tients were placed on the waiting list. Finally, 57 patients
received a transplantation. Two patients died during the trans-
plantation phase and nine patients died during the follow-up.
During the screening phase, patients may be rejected, screen-
ing may be deferred, or patients do not contact the lung
transplantation team for .12 months. With exception of the
application phase, for all phases and for all patients, length of stay
was registered, with the reason for leaving the phase. Further-
more, all costs (direct medical, direct nonmedical, and indirect
nonmedical) and data on quality of life were collected. In
addition, several other patient characteristics were registered, of
which we used diagnosis, age, body length, and blood type.
Diagnosis and age were used as explanatory variables for length
of stay in various phases and for survival. Length and blood type
were used for matching donor and recipient.
For the same period, we also collected data on donor lungs:
acquisition date of the lung and length and blood type of the
donor.
Quality of Life
The health-related quality of life of the patients was measured
through a self-administered questionnaire. It contained several
domain-specific instruments (Karnofsky Performance Index, In-
dex of Well-Being, Self-rating Depression Scale, State-Trait
Anxiety Inventory, activities of daily living) and two generic
instruments: the Nottingham Health Profile and the EuroQol.
Patients were asked to fill out the questionnaire at the entry of
the outpatient screening phase, and from then on every 3 months.
Following transplantation, quality of life was measured after 1, 4,
and 7 months and from then on every 6 months.
In this analysis, effectiveness is measured both as life-years
gained and quality-adjusted life-years (QALY) gained. For the
latter, it is necessary to express quality of life as a number
between 0 and 1 (utility), where 0 represents the worst possible
health state, and 1 the best. The EuroQol group has developed an
algorithm that allows the calculation of the utility that represents
the health state reported by the patient.5 Note that this utility
reflects the value the general population assigns to health states.
Table 1 presents the average quality of life (as measured by the
EuroQol score) of patients who did not die while on the waiting
list. It shows that the health-related quality of life, already poor
during the screening, deteriorates further if patients remain on
the waiting list for a year or longer. For patients who died within
1 year after being placed on the waiting list, the utility was lower:
on average, 0.4 (n510). For those patients, the utility in the 3
months before death was 0.31.
Immediately after transplantation, while the patient is still in
the hospital, for survivors the average utility has increased to 0.69
(n524) and improves further, reaching normal values. Table 2
presents the utilities associated with patients’ quality of life
during the outpatient follow-up phase. The other quality of life
instruments also showed a substantial improvement of quality of
life after transplantation.6
In all phases, except for the waiting list, fewer than five
observations were available of quality of life during the last 3
months before death. Therefore, we assume that in every phase,
patients’ quality of life is 0.30 during the last 3 months before
death. Furthermore, for the phases until outpatient follow-up, we
have used the utilities as presented before. For the first 2 years
of outpatient follow-up, we have assumed that quality of life has
a value of 0.85; after 2 years, this increases to 0.90.
Costs
Data on all direct medical, direct nonmedical, and indirect
nonmedical costs, ie, value of production losses (paid or unpaid
work), related to the lung disease, were gathered for all patients,
from the moment they entered the outpatient screening phase
until they left the program. Where possible, full resource costs
were estimated (base year 1992).7 Table 3 presents for each
phase the average costs per patient per cost category. (Please
note that values and rate of exchange [G15US$0.6] are those in
effect at the time of the study, where G5Netherlands guilders).
The highest costs occur during inpatient screening, on the
waiting list, in the transplantation phase, and during follow-up. In
general, average costs per patient are higher than median costs
and SDs are substantial, reflecting skewed distributions of costs
(Table 3). This skew is due to a minority of patients causing very
high costs (eg, due to complications). This pattern is very normal
in numerous studies of medical consumption.8
We used the sum-limit method as described by van Hout et al9
to calculate cumulative costs by length of stay per phase, per
patient, and per reason for leaving the phase. These cumulative
costs were then used to extrapolate the cost data beyond the
Table 1—Quality of Life on Waiting List*
Phase Screening
Waiting List
0-6 mo 6-9 mo 9-12 mo 12-15 mo .15 mo
Utility 0.52 0.55 0.50 0.45 0.40 0.40
(SD) (0.2) (0.16) (0.18) (0.2) (0.15) (0.12)
N 169 30 30 27 18 11
*Patients who did not die while on waiting list. Average EuroQol score and SDs (in parentheses).
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observation period (or beyond the date for which fewer than five
observations were available). Almost all cumulative costs could be
estimated by a linear function or by a combination of two linear
functions (R2.95%). For instance, for patients who died during
the inpatient screening phase, direct nonmedical costs were G
104 per week whereas indirect nonmedical costs were G 174 per
week in the first 15 weeks, and from then on G 110 per week.
Costs for the situation without transplantation were derived
from the cost data as gathered for the situation with the
transplantation program. It was assumed that until transplanta-
tion, the conventional treatment of patients was not influenced by
the existence of the transplantation program. The following cost
categories are only relevant in case of a transplantation program:
all direct medical costs within the University Hospital Groningen
(except for a few patients who receive their conventional treat-
ment in Groningen), all costs in the transplantation phase and
follow-up, indirect nonmedical costs during the inpatient screen-
ing phase, conditioning costs on waiting list (medication, special
diets, and physiotherapy), and traveling costs to Groningen.
Survival
To estimate survival without transplantation, survival on the
waiting list was used, by defining transplantation as censoring. A
parametric model (Weibull) was used to estimate survival, thus
allowing extrapolation beyond the observation period. Figure 1
shows both the product limit and the parametric estimates for
survival on the waiting list.
After transplantation, the 1- and 2-year survival rates were 86%
and 75%, respectively. Not enough data were available to extrap-
olate survival beyond 3 years. We therefore combined our data
with international data on survival after heart and lung transplan-
tation.1,10 The data available from the St. Louis International
Lung Transplant Registry clearly show that cumulative survival
after lung transplantation decreases with 5%/yr from year 3 till
year 6. Furthermore, data on heart transplantation show that after
1 year, the cumulative survival decreases with 4%/yr until year 11.
Combining this information, we have estimated survival after trans-
plantation for the first 3 years with a Weibull model and after 3
years, cumulative survival decreases with 5%/yr (Fig 2).
Method
A microsimulation model was used to calculate the cost-
effectiveness of the Dutch lung transplantation program in the
next 15 years. A period of 15 years was chosen to make sure that
a steady state was reached, ie, a situation in which the number of
Figure 1. Product-limit and parametric estimates for survival on
the waiting list for lung transplantation.
Table 2—Quality of Life After Transplantation*
Phase
Follow-up
1-3 mo 4-6 mo 7-12 mo 13-19 mo 20-25 mo .25 mo
Utility 0.83 0.85 0.84 0.86 0.91 0.90
(SD) (0.16) (0.14) (0.15) (0.12) (0.1) (0.12)
N 30 24 17 15 12 11
*Average EuroQol score and SDs (in parentheses).
Table 3—Average Costs per Patient per Phase During Study Period*
Phase
Direct Medical Costs
Within UHG (G)
Direct Medical Costs
Outside UHG (G)
Direct Nonmedical
Costs† (G)
Indirect Nonmedical
Costs‡ (G)
Outpatient screening 964 (260/1,941) 8,107 (2,583/16,289) 1,244 (590/1,859) 2,678 (1,010/4,326)
Inpatient screening 24,334 (22,587/14,003) 10,290 (8,092/8,441) 2,749 (2,302/2,095) 4,966 (3,752/5,711)
Pretransplantation 603 (37/1,459) 3,471 (1,453/6,155) 691 (465/1,344) 838 (570/1,078)
Waiting list 16,448 (9,299/23,043) 30,174 (20,736/28,380) 5,099 (4,255/4,403) 9,372 (7,178/8,917)
Transplantation 82,557 (67,956/44,228) 121 (0/329) 602 (451/608) 121 (15/234)
Inpatient follow-up 55,766 (53,796/21,005) 517 (0/948) 1,401 (1,076/1,248) 522 (0/950)
Outpatient follow-up 71,521(70,129/47,422) 39,186 (28,473/30,964) 5,589 (5,130/3,989) 6,966 (3,429/9,368)
(on average 510 days)
*1G5US$0.6. Median costs and SDs in parentheses (median/SD). UHG5University Hospital Groningen; G5Netherlands guilders.
†Such as travel costs, diet costs, costs of medical supplies.
‡Costs of absence from work (paid work and unpaid work, eg, household work).
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patients per pretransplantation phase is stable. After these 15
years, no transplantations are performed, but survival, costs, and
quality of life are calculated for a follow-up period of 25 years
after the program has stopped; thus, the total evaluation period is
40 years.
The model simulates individual patient histories, containing
the exact date a patient enters and leaves a phase. By linking
length of stay in each phase with cost and quality of life estimates,
the total costs and effects of the program are estimated. To
simulate length of stay in, for instance, the outpatient screening
phase, four distributions were estimated, based on the Groningen
data: one regarding duration until death, one until referral to the
next phase, one until rejection, and one until the patient had not
contacted the lung transplantation team for .12 months. These
distributions were estimated by means of survival analysis, thus
allowing for censoring of the data. If the duration distribution
until death is estimated, censoring will occur if the patient is
rejected, referred, or “has no contact,” or if no event has taken
place before the end of the study. With the same technique,
duration distributions for the other three events are calculated.
Using these distributions, for every patient and for each of the
four events, a date for the event is simulated. The event related
to the first of these dates is assumed to have taken place. If the
event is referral to the next phase, this procedure is repeated until
the patient leaves the program or dies.
First, only patient history until waiting list is simulated. For
every patient on the waiting list, a date of death is simulated using
the cumulative survival curve as presented in Figure 1. This
reflects the situation without transplantation program. So, by
using this simulation method, a control group was constructed.
Subsequently, a fixed number of donor lungs is simulated to
become available, distributed randomly over a year. When a
donor lung becomes available, the model checks the waiting list,
and of those patients having the appropriate blood type and body
length, the longest-waiting patient receives the donor lung. From
that moment, the date of death as predicted earlier is canceled
and a new date of death according to survival after transplanta-
tion is simulated.
After having simulated patient histories, costs and effects were
linked to each phase. Then, costs and effects were summed per
year, and for years 1 to 15, the fixed program costs were added.
To take into account different time profiles for costs and effects,
both costs and effects were discounted by 5%/yr, taking year 1 as
the base year.
In the baseline scenario, which is basically the situation of
1995, it is assumed that every year the program is effective, 100
patients enter the outpatient screening phase and 17 donor lungs
are approved for transplantation.
The cost-effectiveness of two other scenarios will be assessed
as well. First, it is anticipated that the baseline scenario will show
a rapid increase of the number of patients on the waiting list, due
to the small number of available donor lungs. Therefore, a
scenario (the policy scenario) will be assessed in which the
number of patients entering the program is restricted.
Second, it has been estimated that with extensive effort, the
supply of donor lungs in the Netherlands may be increased to
27/yr.3 In the donor scenario, the impact of such an increase on
the cost-effectiveness of the program is calculated.
Results
Baseline Scenario
Patient Flow: Each program year, 100 patients will
enter the outpatient screening phase. After 4 years,
the number of patients per year who enter a specific
phase becomes stable: 65 patients enter the inpatient
screening; 50 patients are placed on the waiting list;
and 17 undergo transplantation.
The first years of the program, more patients enter
the waiting list than leave (either because of trans-
plantation or death). After 10 program years, the
number of patients on the waiting list at the end of
the year stabilizes (n5105). In this situation, 50
patients enter the waiting list, 17 undergo transplan-
tation, and 33 die. During the 15 program years, the
number of patients in the follow-up phase at the end
of each year increases. This reflects the fact that each
year, more patients undergo transplantation than die.
The number of deaths per year during the follow-up
phase is 12 in year 10, and 15 in year 15.
Because survival, both on the waiting list and after
transplantation, differs for each diagnosis group, we
also studied the distribution across diagnosis groups
before and after transplantation. In the outpatient
phase, 42% of patients have emphysema/COPD vs
58% of the patients with transplants. The percentage
of patients with pulmonary hypertension drops from
17% in the outpatient screening phase to 11% after
transplantation; for lung fibrosis patients, the per-
centage decreases from 19 to 10%. The share of
patients having cystic fibrosis or other diagnoses
remains the same before and after transplantation.
Costs: The total discounted costs with the program
amount to G 246 million and without the program to
G 130 million. Table 4 presents the total costs in four
categories for the evaluation period of 40 years.
For the situation with the program, the costs
outside the transplant center are the highest,
whereas during the study period 1991 to 1995, the
costs inside the transplant center dominated. This is
explained by the rapid increase of the number of
patients on the waiting list, predicted with the
Figure 2. Product-limit and parametric estimates for survival
after lung transplantation.
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simulation model. Patients on the waiting list induce
much higher costs outside the center.
Health Effects: Without discounting, the total
number of life-years during the evaluation period (40
years), in the situation with the program, amounts to
5,494. The number of life-years gained, compared to
the situation without program, are 1,232. The total
number of transplantations during the evaluation
period are 242, yielding 5.1 life-years gained per
patient with transplant. The number of QALYs
gained is somewhat higher: 1,358, due to the large
difference between quality of life on the waiting list
and after transplantation. Table 5 presents both
life-years and QALYs after discounting by 5%/yr.
The total costs per life-year gained (after discount-
ing) amount to G 194,000 (Table 6), the costs per
QALY gained are lower: G 167,000. If only direct
medical costs are taken into account, the cost-
effectiveness ratios are slightly lower. From Table 6
it is clear that the cost-effectiveness ratios are nota-
bly influenced by discounting: the cost per life-year/
QALY gained increased by 15 to 20% after dis-
counting.
Policy Scenario
In the baseline scenario, two thirds of patients on
the waiting list die, which is a highly undesirable
situation, both for the patients and for the physicians
involved in the program. Therefore, we calculated
cost-effectiveness if the program inflow is restricted
in such a way that the number of patients admitted to
the outpatient screening is such that no more than
50% of the patients eventually die on the waiting list
(assuming that the probability of entering the waiting
list remains unchanged). This would mean that no
more than 68 patients per year should enter the
outpatient screening phase. Of these 68 patients, 35
would be placed on the waiting list, and 17 patients
would then undergo transplantation per year. If the
number of patients entering the program would
decrease to ,65, not enough patients would be on
the waiting list to find a match for all 17 donor lungs.
After 10 years, a steady state would be reached,
where at the end of the year, 55 patients would be
waiting for transplantation.
In this scenario, the additional costs with the
program, after discounting, amount to G 95 million,
G 22 million less than in the baseline scenario. The
number of life years gained and QALYs gained are
550 and 656, respectively (after discounting). Thus,
the costs per life-year gained are more favorable, G
172,000, and the costs per QALY gained are G
144,000. If only direct medical costs are taken into
account, these ratios are G 168,000 and G 141,000,
respectively.
Donor Scenario
In this scenario, the number of patients entering
the screening phases and waiting list are the same as
in the baseline scenario. From year 4 on, 27 patients
undergo transplantation per year, whereas 23 pa-
tients die on the waiting list. In the steady state,
which is reached after 10 years, the number of
patients waiting for a transplant is 75, compared to
100 in the baseline scenario.
With 100 patients entering the outpatient screen-
ing each year, all 27 available donor lungs match with
at least one patient on the waiting list. If the number
of patients entering the program falls below 95, this
may not always be the case.
The total costs in this scenario are 26% higher than
in the baseline scenario, G 147 million. The number
of life years gained and QALYs gained are about 55%
higher, 923 and 1,089, respectively. The cost-effec-
tiveness ratios are G 159,000 per life-year gained and
G 135,000 per QALY gained (after discounting costs
and effects).
Very recently, the legislation in the Netherlands
concerning organ donation has changed.11 The pre-
vious system assumed no permission for donation,
Table 4—Baseline Scenario*
Direct Medical Costs
Inside UHG
Direct Medical Costs
Outside UHG
Direct Nonmedical
Costs
Indirect Nonmedical
Costs Total
Costs with program 88 112 16 30 246
Costs without program 0 88 13 29 130
Incremental costs 88 24 3 1 116
*Total costs for the full evaluation period, per type of costs, discounted by 5%, in million guilders. Costs are for 1992. See Table 3 footnotes for
explanation of abbreviations.
Table 5—Baseline Scenario*
Life-yr QALYs
Effects with program 3,264 1,996
Effects without program 2,664 1,297
Life-years or QALYs gained 600 699
*Life-years and QALYs for the full evaluation period, discounted by
5%.
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unless explicit permission was given by the donor (eg,
by means of a “donor codicil”) or his/her relatives. In
the new system, any Dutch citizen will be invited to
fill in a response card giving (or not) permission to
donate specific organs. A national registry will keep
an up-to-date database of these responses, which can
be consulted if necessary. It is expected that if this
system is fully operational, the number of donor
organs will increase.
Sensitivity Analysis
The lifelong use of immunosuppressive medica-
tion during follow-up after transplantation is a major
element in the costs of lung transplantation. For one
of the most often used immunosuppressive drugs,
cyclosporine, the future costs may fall as a result of
completing the patent period. It is difficult to predict
the extent of a possible price decrease. However, if
we would assume a 50% cost reduction in follow-up
medication, total incremental costs for the baseline
scenario would fall by G 11.8 million (5% discount-
ing). The costs per life-year gained (and per QALY
gained) would be 10% lower.
However, new, more expensive, immunosuppres-
sive medication is already being used. Widespread
application of these drugs will lead to cost increases,
but this might be offset by a better survival and/or
less drug toxicity, which may improve quality of life.
During the inpatient screening phase, patients are
hospitalized for several weeks in the University
Hospital Groningen to undergo an extensive number
of tests. As lung transplantation is still relatively new,
it may be expected that evaluation of the screening
process will result in a more limited, but equally
effective, screening in the future. If the costs of
inpatient screening in the transplant center could be
halved, incremental costs and cost per life-year (and
QALY) gained would decrease by 6% in the baseline
scenario.
The long-term survival after lung transplantation is
still very uncertain. If future long-term survival
would deviate significantly from the survival as as-
sumed above, it could clearly result in a substantial
change in effectiveness. The influence on cost-effec-
tiveness could be considerable, but depends also on
the specific costs during the additional life-years
gained.
Discussion
Lung transplantation is an expensive, but effective
intervention; survival and quality of life improve
substantially after transplantation. This analysis sug-
gests that regardless which scenario would effectuate
in the near future, lung transplantation remains
expensive in terms of costs per life-year (or QALY)
gained.
Crucial elements determining cost-effectiveness
are the number of patients screened and placed on
the waiting list as compared to the number of
available donor organs as well as the substantial costs
of follow-up after transplantation. As more patients
are screened and more patients are waiting (longer)
for transplantation, then more costs are incurred
without any gains in health effects. Restricting the
inflow in the screening phase (eg, being even more
restrictive concerning contraindications) can im-
prove the balance between the costs of screening and
the health effects of transplantation.
We did not try to establish a true “optimal sce-
nario” in terms of cost-effectiveness, but combining
the policy and donor scenario (restricted inflow and
more donors) would result in G 151,000 per life-year
gained (G 124,000 per QALY), which is slightly more
favorable than the results of the donor scenario. This
scenario has the disadvantage that not all donor
organs will be used for transplantation.
The quality of life and utility scores for patients
with transplants improved substantially. This is in
accordance with the findings of Ramsey et al12 for
lung transplantation patients. About the same im-
provements in utility scores were found in the Dutch
heart transplantation study.9
Sensitivity analysis showed that a more limited
inpatient screening process could result in some cost
reduction. However, the feasibility of such a ratio-
nalization should first be investigated.
Comparison with Dutch programs for heart and
liver transplantation shows that cost-effectiveness for
lung transplantation is relatively unfavorable. Costs
per life-year gained (5% discounting) for heart and
liver transplantation were G 66,0009 and G 54,00013
(costs adjusted to 1992).
This difference cannot be explained fully by dif-
ferent methods of analysis or inclusion of different
Table 6—Baseline Scenario*
Costs per Life-Year Gained (G) Costs per QALY Gained (G)
0% Discount 5% Discount 0% Discount 5% Discount
Direct medical costs 155,000 188,000 140,000 161,000
Total costs 162,000 194,000 147,000 167,000
*Costs per life year/QALY gained of lung transplantation. Costs are for 1992 and are given in Netherland guilders (G).
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cost categories. For heart and liver transplantation,
the average number of life-years gained per patient
with transplant is higher: 10.5 and 7.6 years, respec-
tively.
Furthermore, the costs during a year on the
waiting list or a year of follow-up after transplanta-
tion are substantially higher for lung transplantation
as compared to heart and liver transplantation.
In the meantime, the Dutch National Health
Insurance Board advised the minister of Health
Affairs for the moment not to include lung transplan-
tation in the benefit package. The transplantation
program will proceed (subsidized by a development
grant) but further research should indicate if costs
can be reduced, especially during the screening
phase (by reducing the number of patients screened
and/or lowering the costs per patient screened) and
the follow-up phase.
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